Cash, cash equivalents, and short-term investments of $113.1 million as of December 31, 2024, extend operational runway into the first quarter of 2026. Completion of enrollment in the ENERGY 3 pivotal ...

Plans to Focus on Phase 3 Programs in Allergic Conjunctivitis, Dry Eye Disease, and Proliferative Vitreoretinopathy Expected to Extend Company’s Cash Runway Through the End of 2021 Ophthalmology Drug ...

The human genome contains approximately 1,600 types of transcription factors responsible for regulating gene activity across more than 400 tissue and cell types. Chromatin immunoprecipitation ...

After a thorough strategic review, Spok is reducing operating expenses, delivering in excess of $6.0 million in anticipated annual cost savings, along with an approximately 10% workforce reduction.

People sometimes finish the workday and reflect, “I feel like I was busy all day, but I didn’t get anything done.” If that sounds like someone you know, they could benefit from prioritizing how they ...

FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--#AI--iQor, a leading managed services provider of digitally enabled business process outsourcing solutions, today announced a rigorous IT prioritization process ...

Douglas, a technical analyst, came to me having gained extensive experience within a niche market, seeking to transition into an analyst or market research role. He had developed a two-page resume ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry ...